Latest Articles
Organon abandons endometriosis pain drug development after trial failure - MarketScreener
Organon abandons endometriosis pain drug development after trial failure MarketScreener
Published: July 2, 2025, 11:52 a.m.
Organon halts development of endometriosis pain drug after trial failure - Investing.com
Organon halts development of endometriosis pain drug after trial failure Investing.com
Published: July 2, 2025, 11:42 a.m.
Endometriosis linked to four-times higher pregnancy rates than other causes of infertility, study reveals - Medical Xpress
Endometriosis linked to four-times higher pregnancy rates than other causes of infertility, study reveals Medical Xpress
Published: July 2, 2025, 11:33 a.m.
Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... - Medical Dialogues
Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... Medical Dialogues
Published: July 2, 2025, 11:31 a.m.
Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued - Stock Titan
Organon's Promising Endometriosis Drug OG-6219 Falls Short in Critical Phase 2 Trial, Program Discontinued Stock Titan
Published: July 2, 2025, 11:30 a.m.
Doctor shares 6 causes of painful periods after pregnancy and how to reduce pain | Health - Hindustan Times - Hindustan Times
Doctor shares 6 causes of painful periods after pregnancy and how to reduce pain | Health - Hindustan Times Hindustan Times
Published: July 2, 2025, 8:39 a.m.
Greenock bank branch could be under threat after £2.65bn takeover is agreed - Greenock Telegraph
Greenock bank branch could be under threat after £2.65bn takeover is agreed Greenock Telegraph
Published: July 2, 2025, 7:59 a.m.
AstraZeneca Pharma India gains CDSCO approval for treating endometrial cancer in the country - Express Pharma
AstraZeneca Pharma India gains CDSCO approval for treating endometrial cancer in the country Express Pharma
Published: July 2, 2025, 7 a.m.
AstraZeneca Pharma India gets CDSCO nod for expanded use of Imfinzi in Endometrial Cancer - Medical Dialogues
AstraZeneca Pharma India gets CDSCO nod for expanded use of Imfinzi in Endometrial Cancer Medical Dialogues
Published: July 2, 2025, 6:31 a.m.
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - Nature
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion Nature
Published: July 2, 2025, 5:48 a.m.
Link copied to clipboard!